Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET

Company Participants

MarDee Haring-Layton - CAO
Sabrina Martucci Johnson - President and CEO

Conference Call Participants

Catherine Novack - JonesTrading

Brian Kemp Dolliver - Brookline Capital Markets

Douglas Tsao - H.C. Wainwright

Operator

Welcome to the conference call hosted by Daré Bioscience to review the company's Third Quarter Financial Results and to provide a general business update. This call is being recorded. My name is Desiree and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer and MarDee Haring-Layton, Chief Accounting Officer.

Ms. Haring-Layton. Please proceed.

MarDee Haring-Layton

Good afternoon and welcome to the Daré Bioscience financial results and business update call for the quarter ended September 30, 2024. Today we will review our third quarter results and discuss developments and expectations for our pipeline and portfolio.

I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements.

Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by cautionary statements in the company's SEC filings, including our Form 10-Q for the quarter ended September 30, 2024 which was filed today.

I would also like to point out that the content of this call includes time sensitive information that is current only as of today, November 14, 2024. Daré undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call except as required by law.

I will now turn it over to Sabrina.

Sabrina Martucci Johnson

Thank you and thank you for joining the call today. We have a number of updates to cover including regarding the over $20 million in non-dilutive funding that we announced in just the last 30 days. So, we very much look forward to taking you through them.

We believe Daré is the only publicly traded company focused solely on women's health pharmaceutical product development broadly across contraception, sexual health, pelvic pain, fertility, infectious disease and menopause. And we remain dedicated to advancing disruptive products for the health and wellbeing of women through clinical development, regulatory review and ultimately to market.